Korean J Gastroenterol.  2021 Oct;78(4):219-226. 10.4166/kjg.2021.099.

Safety/Efficacy of Prucalopride in Korean Patients with Chronic Constipation: Post-marketing Surveillance

• Yeon SE
• Kim SY
• Chung WC
• Jeon SW
• Park SJ
• Choi CH
• Choi MG

• KMID: 2521496
• DOI: http://doi.org/10.4166/kjg.2021.099

Abstract

Background/Aims
Constipation is a common gastrointestinal disorder. Prucalopride is a dihydrobenzofurancarboxamide derivative with gastrointestinal prokinetic activities and is recommended as an appropriate choice in patients unresponsive to laxatives. This study assessed the safety and efficacy of prucalopride in Korean patients with chronic constipation, in whom laxatives were ineffective.
Methods
This prospective, non-interventional post-marketing surveillance of prucalopride was conducted from 2012 to 2018 at 28 hospitals in Korea. Adults who received prucalopride for the symptomatic treatment of chronic constipation were included. The patients received 2 mg of prucalopride once daily or 1 mg once daily in patients older than 65 years. The baseline characteristics, adverse events (AEs), and seven-point scale of Clinical Global Impression-Improvement were collected.
Results
Of 601 patients, 67.7% were female, and the mean age was 62.3 years. Three hundred patients (49.9%) were older than 65 years. At the baseline, 70.0% of patients reported less than two instances of spontaneous complete bowel movements per week. AEs were reported in 107 patients (17.7%), including headache (3.2%) and diarrhea (2.8%). Seven serious AEs (SAEs) were reported in five patients (0.8%). The SAEs were resolved without complications; there were no cases of death. All SAEs were assessed as ‘unlikely’ causality with prucalopride. In 72.7% of patients, chronic constipation was improved by the prucalopride treatment during the study period.
Conclusions
This study demonstrated the promising safety and efficacy profile of prucalopride in clinical practice. Thus, prucalopride should be considered in patients with chronic constipation when bowel symptoms are refractory to simple laxatives.

Keyword

Constipation; Prucalopride; Korea; Real clinical practice; Adverse events

Reference

1. Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association. 2013; American Gastroenterological Association medical position statement on constipation. Gastroenterology. 144:211–217. DOI: 10.1053/j.gastro.2012.10.029. PMID: 23261064.

2. Kim SJ, Park KS. 2017; Pharmacotherapy in patients with chronic constipation. Korean J Gastroenterol. 70:64–71. DOI: 10.4166/kjg.2017.70.2.64. PMID: 28830131.

3. Jun DW, Park HY, Lee OY, et al. 2006; A population-based study on bowel habits in a Korean community: prevalence of functional constipation and self-reported constipation. Dig Dis Sci. 51:1471–1477. DOI: 10.1007/s10620-006-9087-3. PMID: 16832618.

4. Wald A, Scarpignato C, Kamm MA, et al. 2007; The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 26:227–236. DOI: 10.1111/j.1365-2036.2007.03376.x. PMID: 17593068.

5. Johanson JF, Kralstein J. 2007; Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 25:599–608. DOI: 10.1111/j.1365-2036.2006.03238.x. PMID: 17305761.

6. Shin JE, Jung HK, Lee TH, et al. 2016; Guidelines for the diagnosis and treatment of chronic functional constipation in Korea, 2015 revised edition. J Neurogastroenterol Motil. 22:383–411. DOI: 10.5056/jnm15185. PMID: 27226437. PMCID: PMC4930295.

7. Bharucha AE, Wald A. 2019; Chronic constipation. Mayo Clin Proc. 94:2340–2357. DOI: 10.1016/j.mayocp.2019.01.031. PMID: 31054770. PMCID: PMC6829047.

8. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. 2008; A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 358:2344–2354. DOI: 10.1056/NEJMoa0800670. PMID: 18509121.

9. Forootan M, Bagheri N, Darvishi M. 2018; Chronic constipation: a review of literature. Medicine (Baltimore). 97:e10631. DOI: 10.1097/MD.0000000000010631. PMID: 29768326. PMCID: PMC5976340.

10. Tack J, Stanghellini V, Dubois D, Joseph A, Vandeplassche L, Kerstens R. 2014; Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil. 26:21–27. DOI: 10.1111/nmo.12217. PMID: 24106924. PMCID: PMC4282451.

11. Yiannakou Y, Piessevaux H, Bouchoucha M, et al. 2015; A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 110:741–748. DOI: 10.1038/ajg.2015.115. PMID: 25869393. PMCID: PMC4424376.

12. Ke M, Tack J, Quigley EM, et al. 2014; Effect of prucalopride in the treatment of chronic constipation in Asian and non-Asian women: a pooled analysis of 4 randomized, placebo-controlled studies. J Neurogastroenterol Motil. 20:458–468. DOI: 10.5056/jnm14029. PMID: 25273116. PMCID: PMC4204404.

13. Ke M, Zou D, Yuan Y, et al. 2012; Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 24:999–e541. DOI: 10.1111/j.1365-2982.2012.01983.x. PMID: 22882724. PMCID: PMC3509366.

14. Tack J, Camilleri M, Chang L, et al. 2012; Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 35:745–767. DOI: 10.1111/j.1365-2036.2012.05011.x. PMID: 22356640. PMCID: PMC3491670.

15. Tegaserod: withdrawal from the world market. 2008; A treatment for constipation with cardiovascular adverse effects. Prescrire Int. 17:112–113.

16. Smith WB, Mannaert E, Verhaeghe T, Kerstens R, Vandeplassche L, Van de Velde V. 2012; Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label phase I study. Drug Des Devel Ther. 6:407–415. DOI: 10.2147/DDDT.S36142. PMID: 23269861. PMCID: PMC3529624.

17. Gilsenan A, Fortuny J, Cainzos-Achirica M, et al. 2019; Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 42:1179–1190. DOI: 10.1007/s40264-019-00835-0. PMID: 31134512. PMCID: PMC6739451.